Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double‐blind, placebo‐controlled clinical trial

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Pain

• Publication date

  2007-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pain.2007.08.028PMID 17997224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cannabis in painful HIV-associated sensory neuropathy

  2007influential reference
• Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

  2007cited by this paper
• EFNS guidelines on pharmacological treatment of neuropathic pain

  2006cited by this paper
• Interactions between THC and cannabidiol in mouse models of cannabinoid activity

  2006influential reference
• Morphine, gabapentin, or their combination for neuropathic pain.

  2005cited by this paper
• Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

  2005cited by this paper
• A role for cannabinoid CB1 receptors in mood and anxiety disorders

  2005cited by this paper
• Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats

  2005influential reference
• Morphine, gabapentin, or their combination for neuropathic pain.

  2005cited by this paper
• Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy.

  2004cited by this paper
• A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215)

  2004cited by this paper
• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation

  2004influential reference
• Systemic lidocaine in pain due to peripheral nerve injury and predictors of response

  2004cited by this paper
• Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

  2004influential reference
• Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

  2004cited by this paper
• Cannabis is more than simply Δ9-tetrahydrocannabinol

  2003cited by this paper
• Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.

  2003cited by this paper
• Comment on: Serpell et al., gabapentin in neuropathic pain syndromes: a randomised double-blind, placebo controlled trial (Pain 2002; 99: 557-66).

  2003cited by this paper
• Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial

  2003cited by this paper
• Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

  2003cited by this paper
• Cannabis is more than simply delta(9)-tetrahydrocannabinol.

  2003influential reference
• Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double‐blind, placebo‐controlled study

  2003cited by this paper
• Anticonvulsants in neuropathic pain: rationale and clinical evidence

  2002cited by this paper
• Cardiovascular System Effects of Marijuana

  2002cited by this paper
• Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial

  2002cited by this paper
• A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain

  2002cited by this paper
• Postdelivery of Alfentanil and Ketamine Has No Effect on Intradermal Capsaicin–Induced Pain and Hyperalgesia

  2002cited by this paper
• Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale

  2001cited by this paper
• Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study

  2001cited by this paper
• The stability of the factor structure of the General Health Questionnaire

  2000cited by this paper
• Efficacy of Oral Mexiletine for Neuropathic Pain With Allodynia: A Double-Blind, Placebo-Controlled, Crossover Study

  2000cited by this paper
• Multiple applications of the GHQ-12 in a general population sample: an investigation of long-term retest effects

  2000cited by this paper
• Memantine (a N-Methyl-d-Aspartate Receptor Antagonist) in the Treatment of Neuropathic Pain After Amputation or Surgery: A Randomized, Double-Blinded, Cross-Over Study

  2000cited by this paper
• Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial

  1999cited by this paper
• Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

  1998cited by this paper
• Development and preliminary validation of a pain measure specific to neuropathic pain

  1997cited by this paper
• The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain.

  1997cited by this paper
• The validity of two versions of the GHQ in the WHO study of mental illness in general health care

  1997cited by this paper
• The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study

  1995influential reference
• The Pain Disability Index: psychometric properties

  1990influential reference
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• Validation of the General Health Questionnaire in a young community sample

  1983influential reference
• Tolerance to Delta–9–Tetrahydrocannabinol in the Spontaneously Hypertensive Rat 1

  1973cited by this paper
• Tolerance of delta-9-tetrahydrocannabinol in the spontaneously hypertensive rat.

  1973cited by this paper

• Cannabis-based medicines for chronic neuropathic pain in adults.

  2026cites this paper
• Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study.

  2025cites this paper
• Neuropathic pain management: a focused review of current treatments and novel data from main ongoing clinical trials

  2025cites this paper
• Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.

  2025cites this paper
• Patient-reported outcomes and quantitative sensory testing: are they useful to investigate neuropathic pain mechanisms and predict therapeutic response?

  2025cites this paper
• Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.

  2025cites this paper
• The relationship between cannabis and cardiovascular disease: clearing the haze

  2025cites this paper
• Cannabinoids in neuropathic pain treatment: pharmacological insights and clinical outcomes from recent trials

  2025cites this paper
• Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review

  2025influential citation
• The Efficacy and Safety of Use of Cannabis and Cannabinoid Products for Pain Relief in Orthopaedic Conditions and Trauma

  2025influential citation
• Cannabis for Chronic Pain: Mechanistic Insights and Therapeutic Challenges

  2025cites this paper
• Cannabinoids for Treating Sleep

  2025cites this paper
• Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials

  2025cites this paper
• Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol

  2025cites this paper
• Systematic review and network meta-analysis of the effects of bioactive compounds on pain intensity and quality of life in neuropathic pain patients

  2025cites this paper
• IUPHAR Review: Navigating the role of preclinical models in pain research.

  2024cites this paper
• Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials

  2024cites this paper
• Cannabinoides y dolor PARTE II

  2024cites this paper
• Trends in prescription and cost of Sativex, a cannabinoid-based medicine, in treating patients with multiple sclerosis in England

  2024cites this paper
• SOMATOSENSORY PROFILING OF PATIENTS WITH CLUSTER HEADACHE: A SYSTEMATIC REVIEW AND META-ANALYSIS.

  2024cites this paper
• Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders

  2024cites this paper
• The Effect of E-Cigarette Taxes on Substance Use.

  2024cites this paper
• Cannabiskonsum und Cannabiskonsumstörungen

  2024cites this paper
• The Use of Cannabinoids in the Treatment of Peripheral Neuropathy and Neuropathic Pain: A Systematic Review.

  2024cites this paper
• Cannabidiol and pain.

  2024cites this paper
• The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray.

  2024cites this paper
• Evidence of Cannabidiol Effectiveness Associated or Not with Tetrahydrocannabinol in Topical Administration: A Scope Review

  2024influential citation
• Emerging Therapeutic Modalities and Pharmacotherapies in Neuropathic Pain Management: A Systematic Review and Meta-Analysis of Parallel Randomized Controlled Trials

  2024cites this paper
• Integrative Therapies in Cancer Care: An Update on the Guidelines.

  2024cites this paper
• Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference

  2024cites this paper
• Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation

  2024cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update—Surveillance Report 2

  2023cites this paper
• Medicinal plants for the treatment of neuropathic pain: A review of randomized controlled trials.

  2023cites this paper
• Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial

  2023cites this paper
• Peripherally injected canabidiol reduces neuropathic pain in mice: Role of the 5-HT1A and TRPV1 receptors.

  2023cites this paper
• Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions

  2023cites this paper
• Cannabis products: medical use

  2023cites this paper
• Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis

  2023cites this paper
• CBD as a cure‐all? The impacts of state‐level legalization of prescription cannabidiol (CBD) on opioid prescriptions

  2023cites this paper
• Cannabidiol as an Alternative Analgesic for Acute Dental Pain

  2023cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update—Surveillance Report 3

  2023influential citation
• Medical Cannabis and Its Efficacy/Effectiveness for the Treatment of Low-Back Pain: a Systematic Review

  2023cites this paper
• A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space

  2023cites this paper
• Improving Quality of Life During Chemotherapy: Cannabinoids, Cryotherapy, and Scalp Cooling.

  2023cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update—Surveillance Report 4

  2023influential citation
• Cannabis constituents for chronic neuropathic pain; reconciling the clinical and animal evidence

  2023cites this paper
• Personalized treatment of neuropathic pain: Where are we now?

  2023cites this paper
• Exploring the anti-aging potential of natural products and plant extracts in budding yeast Saccharomyces cerevisiae: A review

  2023cites this paper
• Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19—A Scoping Review

  2023cites this paper
• Effect of Cannabis on Memory Consolidation, Learning and Retrieval and Its Current Legal Status in India: A Review

  2023cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 4

  2022cites this paper
• Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain

  2022cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 2

  2022influential citation
• Cannabinoids – a new therapeutic strategy in neurology

  2022cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 3

  2022influential citation
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 1, September 2022

  2022cites this paper
• Perspectives on Challenges in Cannabis Drug Delivery Systems: Where Are We?

  2022cites this paper
• Cannabis-Based Products for Chronic Pain

  2022influential citation
• Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  2022cites this paper
• Positive Allosteric Modulators of Glycine Receptors and Their Potential Use in Pain Therapies

  2022cites this paper
• Efficacy of cannabis and its constituents in disease management: Insights from clinical studies.

  2022cites this paper
• Use of Cannabidiol in the Management of Insomnia: A Systematic Review

  2022influential citation
• Acetaminophen induced hepatotoxicity: An overview of the promising protective effects of natural products and herbal formulations.

  2022cites this paper
• Direct Regulation of Hyperpolarization-Activated Cyclic-Nucleotide Gated (HCN1) Channels by Cannabinoids

  2022cites this paper
• Hydroethanolic extract of Lavandula angustifolia ameliorates vincristine-induced peripheral neuropathy in rats

  2022cites this paper
• Medicinal Cannabis and Central Nervous System Disorders

  2022cites this paper
• “The Two Sides of the Same Coin”—Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained

  2022cites this paper
• Oral capsules of tetra‐hydro‐cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment

  2022influential citation
• The effects of recreational marijuana legalization on employment and earnings

  2022cites this paper
• Complex regional pain syndrome

  2022cites this paper
• Efficacy of topical cannabinoids in the management of pain: a systematic review and meta-analysis of animal studies

  2022cites this paper
• Cannabinoid CB1 Receptor Expression and Localization in the Dorsal Horn of Male and Female Human and Rat Spinal Cord Tissue

  2022cites this paper
• Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain

  2022cites this paper
• Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028)

  2022cites this paper
• Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry

  2022cites this paper
• Cannabis, cannabinoids, and cannabis-based medicines: future research directions for analgesia

  2022cites this paper
• Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?

  2022cites this paper
• Medical Cannabis and Cannabinoids for Impaired Sleep: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

  2021cites this paper
• CB1 Cannabinoid Receptor Signaling and Biased Signaling

  2021cites this paper
• Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials

  2021influential citation
• Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older

  2021influential citation
• The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial

  2021cites this paper
• Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry

  2021cites this paper
• Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline

  2021cites this paper
• Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials

  2021cites this paper
• Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review

  2021cites this paper
• Cannabinoid Modulation Of Cisplatin Induced Neuropathy

  2021cites this paper
• The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain

  2021cites this paper
• Cannabinoids and chronic pelvic pain in women: Focus on endometriosis

  2021cites this paper
• Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain

  2021cites this paper
• Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment

  2021cites this paper
• Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis

  2021influential citation
• Nabiximols (Sativex®)

  2021cites this paper
• Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis

  2021cites this paper
• Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases

  2021cites this paper
• TIBBİ KENEVİR VE SAĞLIK: FARMAKOLOJİK BİR DERLEME

  2021cites this paper
• Cannabinoid-Related Adverse Events and Impairment

  2021cites this paper
• Nabiximols in chronic neuropathic pain: a meta-analysis of randomized placebo-controlled trials.

  2021cites this paper
• The Role of Cannabis, Cannabidiol and Other Cannabinoids in Chronic Pain. The Perspective of Physicians

  2021cites this paper